Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated November 12, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on November 11, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. It does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased (Nov 11, 2025): 167,000 ordinary shares.
- Price Range: Lowest 1,791.50p; Highest 1,825.00p.
- Volume-Weighted Average Price (VWAP): 1,807.35p.
- Programme Progress: Since September 30, 2025, the company has purchased 8,496,000 ordinary shares.
- Treasury Shares Held: 255,960,844 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,059,467,530 ordinary shares.
- Total Voting Rights: 4,059,467,530.
- Treasury Voting Rights Percentage: 6.31%.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the company. The total number of voting rights remains 4,059,467,530, as treasury shares do not carry voting rights. The percentage of voting rights attributable to treasury shares is confirmed at 6.31% following this purchase.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q3 Results for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the current market price of GSK ordinary shares relative to the VWAP of 1,807.35p paid on November 11, 2025.
- Review the "Risk Factors" in the 2024 Form 20-F and Q3 2025 results for context on the company's broader financial health, as this filing contains no operational data.
- Monitor future filings to track the progression of the buyback programme towards its completion or expiration.